Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 463,711
  • Shares Outstanding, K 103,047
  • Annual Sales, $ 500 K
  • Annual Income, $ -34,000 K
  • 60-Month Beta 2.38
  • Price/Sales 962.46
  • Price/Cash Flow N/A
  • Price/Book 6.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.10
  • Number of Estimates 4
  • High Estimate 0.12
  • Low Estimate 0.08
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +171.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.16 +9.62%
on 11/15/19
5.26 -13.31%
on 11/11/19
-0.51 (-10.06%)
since 11/08/19
3-Month
4.16 +9.62%
on 11/15/19
7.67 -40.55%
on 09/11/19
-2.36 (-34.10%)
since 09/10/19
52-Week
1.85 +146.49%
on 01/02/19
7.67 -40.55%
on 09/11/19
+2.21 (+94.04%)
since 12/10/18

Most Recent Stories

More News
Catalyst Focuses on Firdapse Label Expansion Amid Competition

Catalyst (CPRX) focuses on the development of Firdapse for additional indications.

CPRX : 4.56 (+1.33%)
IRWD : 12.45 (+0.97%)
JAZZ : 150.06 (-0.85%)
FENC : 6.20 (-0.42%)
Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating,...

CPRX : 4.56 (+1.33%)
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.

AGEN : 3.95 (+1.02%)
ANIK : 55.42 (-0.22%)
ALKS : 21.57 (-0.78%)
CPRX : 4.56 (+1.33%)
Catalyst Pharmaceutical (CPRX) Beats Q3 Earnings Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 18.18% and -8.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CPRX : 4.56 (+1.33%)
Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

- Firdapse(R) Launch Momentum Continues with Q3 Net Revenues of $30.9 Million

CPRX : 4.56 (+1.33%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

Pomerantz LLP is investigating claims on behalf of investors of Catalyst Pharmaceuticals, Inc. ("Catalyst" or the "Company") (NASDAQ: CPRX). Such investors are advised to contact Robert S. Willoughby...

CPRX : 4.56 (+1.33%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Pharmaceuticals, Inc. - CPRX

Pomerantz LLP is investigating claims on behalf of investors of Catalyst Pharmaceuticals, Inc. ("Catalyst" or the "Company") (NASDAQ: CPRX). Such investors are advised to contact Robert S. Willoughby...

CPRX : 4.56 (+1.33%)
Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 4.56 (+1.33%)
Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse(R) (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)

CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients

CPRX : 4.56 (+1.33%)
Investors Can Find Strong Stocks with our First Profit Screen

Investors Can Find Strong Stocks with our First Profit Screen

KOS : 5.05 (-2.70%)
FB : 200.87 (-0.23%)
CRSP : 67.63 (+0.27%)
CPRX : 4.56 (+1.33%)
CHRS : 17.82 (+1.42%)
BRFS : 8.82 (-0.34%)
AAPL : 268.48 (+0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade CPRX with:

Business Summary

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis...

See More

Key Turning Points

2nd Resistance Point 4.83
1st Resistance Point 4.69
Last Price 4.56
1st Support Level 4.43
2nd Support Level 4.30

See More

52-Week High 7.67
Fibonacci 61.8% 5.45
Fibonacci 50% 4.76
Last Price 4.56
Fibonacci 38.2% 4.07
52-Week Low 1.85

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar